Administration of DCs electroporated with TriMix mRNA and a melanoma antigen (gp100, tyrosinase, MAGE-A3 or MAGE-C2 fused to DC.LAMP) demonstrated durable clinical benefit in clinical trials involving patients with advanced melanoma when combined with the CTLA-4 inhibitor ipilimumab (114, 115). Here, TYR is linked to melanoma.